News - Tysabri, North America


Current filters:

TysabriNorth America

Popular Filters

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch


The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients


In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available…

AvonexBiogen IdecElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalTysabri

FDA updates Tysabri label relating to anti-JCV


The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Back to top